Sichenzia Ross Ference LLP represented Lexaria Bioscience Corp. in the transaction. Lexaria Bioscience Corp. (NASDAQ: “LEXX”) closed an underwritten public offering of 1,828,571 units, each unit…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
